NEWSROOM

Stock Report

PRISM Q&A CORNER – Ashlee Vogenthaler , Markets Editor, PRISM MarketView

May 1, 2024

Decoding Market Dynamics: An Interview with Ashlee Vogenthaler, PRISM MarketView’s Markets Editor New York, May 01, 2024 - At PRISM MarketView we are proud to feature Ashlee Vogenthaler as our Markets Editor. Ashlee combines a deep understanding of finance and economics with a passion for writing, offering our readers insightful analyses and engaging commentary. Influenced early on by her mother’s finance career and an inspiring high school class, Ashlee developed a keen interest in the stock...

PRISM MarketView Launches Emerging Consumer Products Index

Feb 27, 2024

Emerging companies harness advanced tech to innovate, launch new products, and adapt to inflation in consumer markets New York, N.Y., February 27, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Consumer Products Index. As technologies advance, new innovative products are continuously being developed by emerging companies. These companies play a pivotal role in driving market dynamics and...

Exploring Small-Cap AI Opportunities in a Big-Cap Dominated Market

Exploring Small-Cap AI Opportunities in a Big-Cap Dominated Market

Jan 24, 2024

New York, N.Y., January 24, 2024 - The recent rally in artificial intelligence (AI) investments had a notable exception: small caps. The Street’s James “Rev Shark” DePorre noted the stark contrast between the current AI bubble and the more inclusive Internet bubble of the late 1990s in his column “There is an AI Bubble, but There is No Small-Cap Participation.” He wrote, “During the Internet bubble in 1999-2000…hundreds of small-caps attracted speculative traders and helped drive the...

PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index

Jan 12, 2024

New York, N.Y., January 12, 2024 - In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index. Some of these cancers include breast, gynecological, colorectal and melanoma. The growing PRISM Emerging Women’s Health Index tracks small and micro-cap stocks that focus on a broad range of...

PRISM MarketView Launches Emerging Women’s Health Index

Jan 4, 2024

Global women’s health market projected to reach $67.07 billion by 2031 Private equity investment in women’s health exceeded $3 billion in 2022 New York, N.Y., January 4, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Women’s Health Index. The growth of the women’s health market is accelerating with the introduction of next-generation therapeutics and artificial intelligence (AI) powered imaging and...

Most Popular PRISM MarketView Articles in 2023

Most Popular PRISM MarketView Articles in 2023

Dec 29, 2023

New York, December 29, 2023 - 2023 was a year filled with significant developments in emerging stocks, featuring a wide range of topics from clinical updates and strategic partnerships to earnings reports. Notable stories include Oncocyte’s initiation of the FDA submission process for its kidney transplant monitoring test, SKYX’s partnership with Kichler, and Soluna’s robust Q3 earnings. The year also saw engaging discussions on unique topics like full moon trading, Thanksgiving strategies,...

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Dec 28, 2023

New York, December 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization...

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Dec 28, 2023

New York, December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in developing novel treatments for mental health disorders, has named EB-003 as the lead candidate from its EVM301 Series. This series targets depression, anxiety, and addiction disorders. The selection of EB-003 is a key milestone for Enveric, transitioning the company from a discovery phase to a drug development phase. EB-003 is chosen for its potential to...

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

Dec 27, 2023

New York, December 27, 2023 - Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133 foreign patents. Its dental product, the Single Tooth Anesthesia System (STA), has received FDA and CE marketing clearance in more than 50 countries. The STA system utilizes computer-assisted technology for precise and consistent...

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Dec 27, 2023

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

Dec 22, 2023

New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

Dec 22, 2023

New York, December 22, 2023 - PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. https://prismmarketview.com/companies/petvivo-holdings-inc/ Spryng, the company’s signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals. Earlier this month, the company announced the sale of Spryng to more...

PRISM Analysis: Why Did CareCloud Shares Jump This Week?

PRISM Analysis: Why Did CareCloud Shares Jump This Week?

Dec 22, 2023

New York, December 22, 2023 - Healthcare technology solutions provider, CareCloud, Inc. (Nasdaq: CCLD) has seen a jump in its share price this week. The new momentum is being driven by the company’s financial and operational update, issued on Wednesday, and outlining an attractive roadmap for future growth. Shareholders rewarded CareCloud with a 25.61% increase following Wednesday’s session, and a 22.94% boost on Thursday. https://prismmarketview.com/companies/carecloud-inc/ Remarking on the...

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Dec 21, 2023

New York, December 21, 2023 - In two weeks, 2023 will be history so consider this your reminder to start figuring out a resolution that likely will be forgotten, by this time next year. New Years is celebrated in a multitude of ways based on geography, culture, or religion. However, unlike other holidays, it is one that is observed by mostly everyone around the world. As always, PRISM has you covered as we close out the year and provide you with some “go-to” resolution ideas, highlight some...

Palatin Technologies Sells Vyleesi in $171M Transaction

Palatin Technologies Sells Vyleesi in $171M Transaction

Dec 21, 2023

New York, December 21, 2023 - Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to $171 million. Vyleesi is the first and only as-needed FDA-approved treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). https://prismmarketview.com/companies/palatin-technologies-inc/ Carl Spana, Ph.D., President and Chief Executive Officer of...

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Dec 21, 2023

New York, December 21, 2023 - Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). https://prismmarketview.com/companies/creative-medical-technology-holdings-inc/ Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another...

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

Dec 20, 2023

New York, December 20, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5...

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

Dec 20, 2023

New York, December 20, 2023 - Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). https://prismmarketview.com/companies/lipella-pharmaceuticals-inc/ Today, the company announced it has successfully completed a Type C meeting with...

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Dec 20, 2023

New York, December 20, 2023 - Shares in payment network company, Affirm Holdings (Nasdaq: AFRM), jumped more than 15% on Tuesday after the company announced it would expand its partnership with Walmart to offer a Buy Now, Pay Later (BNPL) service at self-checkout kiosks at over 4,500 Walmart stores in the United States. https://prismmarketview.com/companies/affirm-holdings-inc/ https://prismmarketview.com/buy-now-pay-later-affirm-shares-jump-on-news-of-walmart-partnership/ Pat Suh, Affirm’s...

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

Dec 19, 2023

New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Shares in Battalion Oil Corporation (NYSE American: BATL) surged more than 80% on Friday after the company announced it has agreed to be acquired by Fury Resources, Inc. for $9.80 per share in cash, which represents a total transaction value of approximately $450 million. The transaction is expected to close in the first quarter of 2024. https://prismmarketview.com/companies/trio-petroleum-corp/ Battalion’s CEO, Matt Steele, commented, “It has been a pleasure...

MindMed Advances Treatment for Generalized Anxiety Disorder

MindMed Advances Treatment for Generalized Anxiety Disorder

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements. https://prismmarketview.com/companies/mind-medicine-mindmed-inc/ Robert Barrow, Chief Executive Officer and Director of MindMed,...

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

Dec 16, 2023

In the fast-paced landscape of experiential design and technology, Creative Realities Inc. seamlessly integrates the physical and digital realms in creating immersive experiences that captivate audiences across various industries. NEW YORK, NY, December 16, 2023 - Creative Realities specializes in interactive displays, immersive retail solutions, and cutting-edge content creation to reshape how individuals connect with brands and spaces. With a commitment to innovation and a client-centric...

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

Dec 15, 2023

NEW YORK, NY, December 15, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday. https://prismmarketview.com/companies/neurosense-therapeutics-ltd/ Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue to gain a better...

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

PRISM AdTech & Media Company Spotlight: Creative Realities (CREX) Illuminates the Future of Experiential Design

Dec 14, 2023

NEW YORK, NY, December 14, 2023 - In the fast-paced landscape of experiential design and technology, Creative Realities Inc. ($CREX) seamlessly integrates the physical and digital realms in creating immersive experiences that captivate audiences across various industries. From transforming retail spaces into dynamic environments to utilizing cutting-edge technologies in interactive displays, CREX is reshaping the way we interact with the world....

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - US equities closed mostly higher on Tuesday as the S&P set a fresh year-to-date high, finishing the day at its highest level since January 2022, just 3.2% below its all-time high. Energy stocks underperformed while gasoline prices were down (6%) for the month, playing a key role in cooling inflation numbers for November. The S&P 500 Energy Index was down (1.35%) versus the S&P 500 which rose +0.14%. The XLE settled down (1.39%), the XOP fell...

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share price surged 100% in trading on Wednesday morning. https://prismmarketview.com/companies/reshape-lifesciences-inc/ Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, said, “PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a...

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - Quoin Pharmaceuticals (Nasdaq: QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments. These protocol amendments are being implemented with a view to generating an even more robust data set and potentially more...

PRISM NEXT GEN TECH COMPANY SPOTLIGHT: THE GLIMPSE GROUP’S JOURNEY INTO THE FUTURE

Dec 12, 2023

NEW YORK, NY, December 12, 2023 - An immersive technology platform company, Glimpse recently announced its plans for a strategic shift from current immersive technologies that include virtual-reality headsets, tablets and phones to spatial computing, cloud and AI-driven immersive software solutions. From cutting-edge software development to immersive content creation, Glimpse pushes the boundaries of what is possible in the realm of extended realities....

PRISM MarketView Launches Emerging AdTech and Media Index

Dec 12, 2023

Leading global companies work to strike balance between digital and traditional advertising Industry experts point to 2H 2024 for AdTech and Media IPO market to strengthen NEW YORK, NY, December 12, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging AdTech and Media Index. With a finger on the pulse of the digital media revolution, the PRISM index is tracking emerging companies making a mark on the adtech...